Drug Trial Radar · NCT06700538
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Actual
Start
Dec 4, 2024
Primary completion
Oct 15, 2027
Study completion Feb 15, 2028
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multiple doses of ARO-INHBE either as monotherapy, or in combination with tirzepatide, in adult participants with obesity with and without type 2 diabetes mellitus (in Part 2 and Part 3).
Conditions
- Obesity
Interventions
ARO-INHBEDrug
Subcutaneous (SC) injection
PlaceboDrug
Calculated volume to match active treatment by SC injection
TirzepatideDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Day 365
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Camberwell, Australia
Research Site
Charlestown, Australia
Research Site
Maroochydore, Australia
Research Site
Sydney, Australia
Research Site
Chicoutimi, Canada
Research Site
Concord, Canada
Research Site
Toronto, Canada
Research Site
Tbilisi, Georgia
Research Site 2
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Auckland, New Zealand
Research Site
Auckland, New Zealand
Research Site
Christchurch, New Zealand
Research Site
Grafton, Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.